Dr. Uckelmann continued investigating the mechanism of NPM1c-driven leukemogenesis as an instructor at Harvard Medical School. There she discovered an unexpected role of mutant NPM1 on chromatin representing the molecular basis for the effectiveness of targeted epigenetic therapies in NPM1 mutant AML. NPM1c cooperates with other chromatin factors to change the chromatin landscape and enhance transcriptional output at its target sites.
This new discovery opens up many exciting new avenues of research and potential ways of therapeutic targeting of these leukemias which the Uckelmann lab is planning to explore in the future.
Awards and Honors:
2020 – 2022 The Charles A. King Trust Postdoctoral Fellowship
2020 – 2021 The Mark Foundation for Cancer Research Momentum Fellowship
2017 – 2020 DFG Postdoctoral Fellowship
2018 ASH Abstract Achievement Award
2014 ASH Abstract Achievement Award
2010 Ph.D. Stipend at the DKFZ Helmholtz International Graduate School inre